Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV LID cp ΔM2-2 Vaccine in RSV-Seronegative Infants and Children
NCT02948127Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2016
- Primary completion
- Apr 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing RSV LID cp ΔM2-2 Vaccine with Placebo (2 arms). Primary endpoints: Grades of study product-related solicited adverse events at 28 days, Grades of study product-related unsolicited adverse events at 28 days and 7 more. Started Sep 2016; status: terminated.
02
Drugs
RSV LID cp ΔM2-2 vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02948127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948127.